Скачать с ютуб Cold Agglutinin Disease | Free Online CME в хорошем качестве

Cold Agglutinin Disease | Free Online CME

To claim CME/NCPD please visit this link: https://bit.ly/45Qoh0u In this activity, Catherine M. Broome, MD, Associate Professor of Medicine at Georgetown University School of Medicine, will provide expert guidance on diagnostic features, current treatment standards, emerging therapies, and supportive care strategies for patients with cold agglutinin disease (CAD). Start the activity now! STATEMENT OF NEED Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia (AIHA) in which antibodies cause hemolysis at cold temperatures, generally between 37º to 39º Fahrenheit. Approximately 1 in a million people are affected by CAD annually, with onset usually occurring between the ages of 40 and 80 years. Individuals commonly experience fatigue, dizziness, palpitations, and shortness of breath caused by the anemia; jaundice caused by degradation of hemoglobin into bilirubin; and sweating, coldness, or painful discoloration of their fingers, toes, ankles, and wrists triggered by exposure to cold (NORD, 2020). While progress has been made in recent years in understanding the pathogenesis of CAD, consensus recommendations based on randomized trials are needed for improving treatment outcomes and reducing symptom burden (Berentsen, 2021). In this activity chaired by Catherine Broome, MD, Associate Professor of Medicine at Georgetown University School of Medicine, faculty will provide expert perspectives on optimizing the diagnosis, treatment, and supportive care of CAD. TARGET AUDIENCE Hematology fellows, attending faculty, and other health care professionals involved in the treatment of patients with cold agglutinin disease (CAD). LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: Evaluate the clinical and laboratory features of CAD that can inform timely and accurate diagnosis, discuss the pathophysiology of CAD and the scientific rationale for targeting the classical complement pathway, appraise the efficacy and safety of novel complement inhibitors for CAD as elucidated by recent studies, and assess strategies for managing anemia, cold-induced circulatory symptoms, and treatment-related adverse events to optimize the clinical outcomes of patients with CAD. DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession. A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits. i3 Health will identify, review, and mitigate all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services. Relevant financial relationships exist between the following individuals and commercial interests: The i3 Health planners, reviewers, and managers have nothing to disclose. Catherine M. Broome, MD, discloses that she has served on advisory board or panel for Alexion, Alpine, Argenx, Sanofi, and Star; that she has served on a speaker's bureau for Alexion and Sanofi; and that she has received grants/research support from Alexion, Alpine, Argenx, Novartis, Sanofi, and Star. i3 Health has mitigated all relevant financial relationships. COMMERCIAL SUPPORT This activity is supported by an independent educational grant from Sanofi. Aggregate participant data will be shared with commercial supporters of this activity.